Elicio (ELTX) Director Karen J. Wilson Receives 21,750-Share Award

What Happened
Karen J. Wilson, a director of Elicio Therapeutics, was granted an equity award reported as a derivative for 21,750 shares on August 31, 2026. The filing reports the transaction at $0.00 (derivative grant). This is an annual non-employee director equity award (routine compensation), not an open-market buy or sale.

Key Details

• Transaction date: 2026-08-31; Form 4 filed: 2026-09-02.
• Transaction type/code: Award/Grant (A) reported as a derivative; amount = 21,750 shares; reported price = $0.00.
• Vesting: Award vests in full on the earlier of (A) August 31, 2027 (one-year anniversary) or (B) the issuer’s 2027 annual meeting, subject to continued service.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: No additional equity award will be made to the reporting person in connection with the 2026 annual meeting of stockholders.
• Timeliness: Filing date is 2026-09-02 for an 8/31/2026 grant; the Form 4 appears to have been submitted within standard SEC timing for insider reports.

Context
This was a time-based director equity award (typical non-employee director compensation). As a derivative grant, it does not represent an immediate cash purchase or sale — value is realized only if/when the award vests and is exercised according to plan terms. Routine director awards are common and do not by themselves indicate a change in insider sentiment.